Skip to content

ALGS - Aligos Therapeutics, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchA

Aligos Therapeutics Inc

ALGS · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

A

ALGSAligos Therapeutics Inc

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 21

52-wk high: $13.69
52-wk low: $3.98
Prev close: $9.89
Mkt cap: $43.0M
Beta: 2.28
P/S: 1.4x

Smart money

8 funds hold a position.

Real smart money

Funds holding this stock

8 holders

Combined position$4.4M

MW
Marshall Wace
Q2 2026 13F
$1.4M
position
CI
Citadel
Ken Griffin · Q1 2026 13F

Earnings

Reported Aug 5, 2026

Earnings came in 90.1% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is not yet profitable.

Net margin: -241.0%
Market cap: $43M

Valuation

P/S1.36
P/B1.32

Quality

Operating margin-6.8%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: ALGS
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $43.02M
Beta: 2.28

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

P/B

1.3x

Profit margin

-241.0%

Op margin

-6.8%

ROE

-113.6%

$404K

position

DS

D.E. Shaw

Q2 2026 13F

$383K

position

5 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 holders

Coverage gaps for ALGS

No recent insider trade
No recent Congress trade
No recent market-voice mention

Earnings per share

-$0.14+90.1%

-$1.41 expected

Next report

What the street expects next

-113.6%

ROA-49.1%

Growth

Beta2.28